快而精医药 QGEN 深 沪
已收盘 08-07 16:00:00 美东时间
42.28
+0.570
+1.37%
华盛通- 最 高42.56
- 今 开42.56
- 成交量 240.85万股
- 最 低 40.87
- 昨 收 41.71
- 总市值 959.76万
- 52周最高 57.815
- 市盈率 静 19.14
- 换手率 1060.99%
- 52周最低 32.53
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 59.00
- 量 比 0.72
- 振 幅 4.05%
- 历史最低 11.8701
- 每 手 1
- 风险率 5.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Private equity giants circle Qiagen (QGEN) with potential bids of $50/share. Get the details on the molecular diagnostics buyout.
07-10 21:26
Qiagen Explores Possible Sale After New Buyer Talks: Report
Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest from several buyers.
01-21 21:11
QIAGEN CEO Thierry Bernard To Step Down After Successor Is Named
After six years as CEO, Supervisory Board and Thierry Bernard agree on timing for transition, and for Thierry Bernard to step down after successor is appointed.
2025-11-05 02:12
QIAGEN, Bode Technology Enter Multi-year Agreement For GEDmatch PRO Genealogy Database
The multi-year agreement between QIAGEN's subsidiary Verogen and Bode extends the long-standing partnership of two leading companies in forensic investigative genetic genealogy (FIGG) to further accelerate the use of
2024-09-24 04:10
QIAGEN Expands Strategic Partnership With Bio-Manguinhos/Fiocruz
The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus. With the expansion of this collaboration, Bio-Manguinhos is now
2024-09-13 04:11
Qiagen, Eli Lilly Collaborate on APOE Genotype Test for Alzheimer's Diagnosis
05:40 PM EDT, 09/04/2024 (MT Newswires) -- Qiagen (QGEN) said Wednesday it is collaborating with Eli Lilly (LLY) for the development of QIAstat-Dx in-vitro diagnostic to detect APOE genotypes that can help in the diagnosis of Alzheimer's disease. Qiagen said the panel will be integrated with its QIA...
2024-09-05 05:40
QIAGEN Enters Collaboration With Eli Lilly To Support Development Of QIAstat-Dx In-vitro Diagnostic To Detect APOE Genotypes Which Can Play Role In Diagnosis Of Alzheimer's Disease; No Terms Disclosed
This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping.
2024-09-05 04:29
Qiagen Expands Master Collaboration Agreement with AstraZeneca
05:31 PM EDT, 08/28/2024 (MT Newswires) -- Qiagen (QGEN) said late Wednesday it is expanding its master collaboration agreement with AstraZeneca (AZN). Qiagen will use its QIAstat-Dx syndromic testing platform to develop and validate a genotyping assay that will allow specialty care providers to pot...
2024-08-29 05:31
QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca's future therapies being developed to address chronic diseases. Under the agreement, QIA...
2024-08-29 04:12
